Serum b-cell maturation antigen levels to predict progression free survival and responses among relapsed or refractory multiple myeloma patients treated on the phase I IRUX trial.

Sean Bujarski,Camilia M. Soof,Haiming Chen,Mingjie Li,Eric Sanchez,Cathy S. Wang,Marsiye Emamy-Sadr,Regina A. Swift,Kian J. Rahbari,Saurabh Patil,Tanya M. Spektor,James R. Berenson

Serum b-cell maturation antigen levels to predict progression free survival and responses among relapsed or refractory multiple myeloma patients treated on the phase I IRUX trial.

2018

Sean Bujarski
Camilia M. Soof
Haiming Chen
Mingjie Li
Eric Sanchez
Cathy S. Wang
Marsiye Emamy-Sadr
Regina A. Swift
Kian J. Rahbari
Saurabh Patil
Tanya M. Spektor
James R. Berenson

e24313Background: B-cell maturation antigen (BCMA) is expressed on plasma cells among patients (pts) with multiple myeloma (MM). We have previously shown that the half-life of soluble BCMA is much ...

Keywords:

Refractory Multiple Myeloma
Oncology
B-Cell Maturation Antigen
Progression-free survival
Pathology
Medicine
Internal medicine
Cancer research
Multiple myeloma
Antigen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations